Phase I trial to investigate the effect of renal impairment on isavuconazole pharmacokinetics

PURPOSE: The purpose of the study is to evaluate the effect of renal impairment (RI) and end-stage renal disease (ESRD) on the pharmacokinetics (PK) of isavuconazole and the inactive cleavage product, BAL8728. METHODS: A single intravenous dose of the prodrug isavuconazonium sulfate (372 mg, equival...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Eur J Clin Pharmacol
Auteurs principaux: Townsend, Robert W., Akhtar, Shahzad, Alcorn, Harry, Berg, Jolene K., Kowalski, Donna L., Mujais, Salim, Desai, Amit V.
Format: Artigo
Langue:Inglês
Publié: Springer Berlin Heidelberg 2017
Sujets:
Clinical Trial
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5423998/
https://ncbi.nlm.nih.gov/pubmed/28271239
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00228-017-2213-7
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires